Rheumatoid arthritis therapy and liver disease

Česká verzia

Authors: K. Mintálová
Authors place of work: Revmatologický ústav Praha
Published in the journal: Čes. Revmatol., 31, 2023, No. 4, p. 183-189.
Category: Review Article

Summary

In recent years, we have observed an increase in liver diseases worldwide, most often in the sense of transient elevation of liver enzymes and non-alcoholic steatohepatitis (NAFLD) or non-alcoholic steatohepatitis (NASH). Most of the drugs used in the therapy of rheumatoid arthritis are potentially hepatotoxic (nonsteroidal anti-inflammatory drugs, methotrexate, leflunomide, sulfasalazine, and TNF inhibitors), so it is necessary to take into account possible pre-existing liver disease before and during antirheumatic therapy. Type 2 diabetes mellitus and obesity, which are also increasingly common, contribute to liver damage. The cytokines interleukin 6 and TNF play an important role here. In this review article, we discuss the treatment options for rheumatoid arthritis in relation to possible drug-induced liver damage.

Keywords:

NASH – liver injury – drug toxicity – hepatotoxicity – NAFLD

Zdroje

1. Brůha R, Dvořák K, Fejfar T, et al. Doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu nealkoholové tukové choroby jater. Gastroent Hepatol 2020; 74(2): 103–110.

2. Benhamou JP. Drug induced hepatitis: clinical aspects. In: Fillastre JP. Hepatotoxicity of drug. Rouen: University of Rouen 1985; 2–30.

3. Russo MW, Galanko, JA, Shresta R, et al. Liver transplantation for acute liver failure from drug-induced injury in the United States. Liver Transpl 2004; 10: 1018–1023.

4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285.

5. Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56: 1145–1151.

6. Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis 2015; 11: 137–141.

7. Dvořák K, Hainer R, Petrtyl J, Zeman M, Vařeka T, Žák A, et al. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014.

8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.

9. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082–1090.

10. Zou YW, Li QH, Gao JW, Pan J, Ma JD, Chen LF, et al. Association between metabolic dysfunction-associated fatty liver disease and cardiovascular risk in patients with rheumatoid arthritis: a cross-sectional study of Chinese cohort. Front Cardiovasc Med 2022; 9: 884636.

11. Radovanović-Dinić B, Tešić-Rajković S, Zivković V, Grgov S. Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int 2018; 38(5): 715–724.

12. Licata A. Adverse drug reactions and organ damage: The liver. Eur J Intern Med 2016; 28: 9–16.

13. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol 2016; 81(6): 1030–1036.

14. Cataldi M, Citro V, Resnati C, Manco F, Tarantino G. New avenues for treatment and prevention of drug-induced steatosis and steatohepatitis: much more than antioxidants. Adv Ther 2021; 38(5): 2094–2113.

15. Ezhilarasan D. Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms. Toxicology 2021; 458: 152840.

16. Qiao X, Zhou ZC, Niu R, Su YT, Sun Y, Liu HL, et al. Hydroxy-chloroquine improves obesity-associated insulin resistance and hepatic steatosis by regulating lipid metabolism. Front Pharmacol 2019; 10: 855.

17. Zekić T, Benić MS, Radić M. Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver disease. Rheumatol Int 2022; 42(10): 1665–1679.

18. European Association for the Study of the Liver. Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019; 70(6): 1222–1261.

19. Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol 2015; 14(6): 789–806.

20. García DS, Saturansky EI, Poncino D, Martínez-Artola Y, Rosenberg S, Abritta G, Ascimani-Peña C, Cravero A. Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency? Ann Hepatol 2019; 18(5): 765–769.

21. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21(1): 3–16.

22. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroscanR): a prospective study. Gut 2006; 55: 403–408.

23. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13(4): 643–654.

24. Ehrmann J, Strojil J. Lékové postižení jater – současný stav problematiky se zaměřením na morfologický obraz, Čes-slov Patol 2008; 44(1): 4–7.

25. Doria A, Zavaglia D. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol 2019; 37(5): 862–871.

26. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021; 73(7): 924–939.

27. Lertnawapan R, Chonprasertsuk S, Siramolpiwat S. Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate. Int J Rheum Dis 2019; 22(2): 214–221.

28. Mansouri A, Gattolliat CH, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology 2018; 155(3): 629–647.

29. European Association for the Study of the Liver. Clinical Practice Guideline Panel: Chair:; Panel members; EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019; 70(6): 1222–1261.

30. European Association for the Study of the Liver. Clinical Practice Guideline Panel; Chair:; EASL Governing Board representative; Panel members. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75(3): 659–689.

31. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39(6): 655–665.

32. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al.; CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69(9): 1612–1617.

33. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 2017; 76(5): 840–847.

34. Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012; 39(12): 2238–2246.

35. Veeravalli V, Dash RP, Thomas JA, Babu RJ, Madgula LMV, Srinivas NR. Critical assessment of pharmacokinetic drug-drug Interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved Janus kinase inhibitors for rheumatoid arthritis treatment. Drug Saf 2020; 43(8): 711–725.